로딩 중…
지수 로딩 중…
Relay Therapeutics, Inc.
RLAY· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$18.78-0.27%
2026-08-03
Financials
Valuation Metrics
Relay Therapeutics, Inc.'s Market Cap is $4.03B. At end of 2025 it was $1.45B. Ranked #1554 of 3,112 in US market (top 50%), #539 of 1,445 on NASDAQ (top 37%), #89 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 33%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $4.03B | US#1,554/3,112 Sec#89/269 |
| Revenue | $11M | US#2,921/3,112 Sec#179/269 |
| Net Income | $-273M | US—/3,112 Sec—/269 |
| Total Assets | $700M | US#2,601/3,112 Sec#125/269 |
| Net Assets | $642M | US#2,080/3,112 Sec#87/269 |
| Value | ||
| P/B | 6.27x | US#2,339/3,112 Sec#163/269 |
| P/S | 377.29x | US#2,932/3,112 Sec#192/269 |
| FCF Yield | -5.30% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -42.47% | US#2,704/3,112 Sec#158/269 |
| ROA | -38.98% | US#2,922/3,112 Sec#189/269 |
| Op. Margin | -2776.61% | US#2,938/3,112 Sec#184/269 |
| Revenue Growth | -60.93% | US#2,894/3,112 Sec#168/269 |
| Financial Health | ||
| Debt Ratio | 8.94% | US#90/3,112 Sec#40/269 |
| Total Debt | $32M | US#2,631/3,112 Sec#166/269 |
| FCF | $-213M | US#2,742/3,112 Sec#222/269 |
| Cash | $205M | US#1,709/3,112 Sec#114/269 |
| Current Ratio | 22.13x | US#115/3,112 Sec#28/269 |
| Performance | ||
| 1Y Return | 458.93% | US#23/3,112 Sec#12/269 |
| 1M Return | 0.70% | US#1,543/3,112 Sec#65/269 |
| From 52W High | -9.67% | US#1,013/3,112 Sec#49/269 |
| 1Y MDD | -28.15% | US#1,251/3,112 Sec#78/269 |
| Trading | ||
| Volume | 1,530,660 shares | US#1,101/3,112 Sec#102/269 |
| Trading Value | $28M | US#1,766/3,112 Sec#124/269 |
| Per Share | ||
| EPS | $-1.61 | US—/3,112 Sec—/269 |
| BPS | $3.30 | US#2,390/3,112 Sec#156/269 |